Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47067 | 0.98 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22862014 | 0.98 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL26315916 | 0.98 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL18591853 | 0.98 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL18365026 | 0.98 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL14258531 | 0.98 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL13055393 | 0.92 | TDP1 (0.58) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22276648 | 0.90 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22276641 | 0.90 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL12885084 | 0.90 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| WO-2023114455-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC | 2021-05-06 | — | — | US | disclosed |
| US-8658346-B2 | Pattern forming process, chemically amplified positive resist composition, and resist-modifying composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8426105-B2 | Resist-modifying composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110033799-A1 | PATTERN FORMING PROCESS, CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION, AND RESIST-MODIFYING COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7637941-B1 | Endothelial cell binding coatings for rapid encapsulation of bioerodable stents | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2009-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | TDP1 105/4885MEN1 3599/4885KMT2A 2866/4885 |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | TDP1 3206/4885MEN1 486/4885KMT2A 3995/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | TDP1 1380/4885MEN1 940/4885KMT2A 1974/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | TDP1 2836/4885MEN1 1339/4885KMT2A 4378/4885 |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | PAK2, PAK3, PAK1 | TDP1 988/4885MEN1 1099/4885KMT2A 1073/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | TDP1 2488/4885MEN1 1062/4885KMT2A 1372/4885 |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | TDP1 441/4885MEN1 677/4885KMT2A 2877/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | TDP1 2942/4885MEN1 1351/4885KMT2A 1071/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | TDP1 270/4885MEN1 1512/4885KMT2A 1816/4885 |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | TDP1 823/4885MEN1 1766/4885KMT2A 3543/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | TDP1 3208/4885MEN1 3068/4885KMT2A 427/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | TDP1 1816/4885MEN1 162/4885KMT2A 3576/4885 |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | TDP1 823/4885MEN1 1766/4885KMT2A 3543/4885 |
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | ZC3HAV1, TYMP, ZC3HAV1L | TDP1 270/4885MEN1 1512/4885KMT2A 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.